evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 40%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 0 · 0%High 0 · 0%

POLYPEPTIDE ‐ CERULETIDE vs placebo

Tardive dyskinesia: Deterioration of symptoms · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

POLYPEPTIDE ‐ CERULETIDE showed no clear difference in tardive dyskinesia: Deterioration of symptoms compared with PLACEBO (low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Adverse effects ‐ any adverse effect · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

POLYPEPTIDE ‐ CERULETIDE showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review